TET vs. SYNT, ZTF, ESNT, ELM, AMRQ, LTHM, KMR, CAML, SOLG, and ECOR
Should you be buying Treatt stock or one of its competitors? The main competitors of Treatt include Synthomer (SYNT), Zotefoams (ZTF), Essentra (ESNT), Elementis (ELM), Amaroq Minerals (AMRQ), James Latham (LTHM), Kenmare Resources (KMR), Central Asia Metals (CAML), SolGold (SOLG), and Ecora Resources (ECOR). These companies are all part of the "basic materials" sector.
Synthomer (LON:SYNT) and Treatt (LON:TET) are both small-cap basic materials companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings.
Synthomer presently has a consensus target price of GBX 224.50, indicating a potential downside of 2.39%. Treatt has a consensus target price of GBX 686.67, indicating a potential upside of 81.66%. Given Synthomer's stronger consensus rating and higher probable upside, analysts clearly believe Treatt is more favorable than Synthomer.
Treatt has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks.
In the previous week, Synthomer had 13 more articles in the media than Treatt. MarketBeat recorded 14 mentions for Synthomer and 1 mentions for Treatt. Synthomer's average media sentiment score of 0.38 beat Treatt's score of -0.08 indicating that Treatt is being referred to more favorably in the news media.
Synthomer received 565 more outperform votes than Treatt when rated by MarketBeat users. However, 68.83% of users gave Treatt an outperform vote while only 68.50% of users gave Synthomer an outperform vote.
25.7% of Synthomer shares are held by institutional investors. Comparatively, 68.2% of Treatt shares are held by institutional investors. 27.0% of Synthomer shares are held by company insiders. Comparatively, 12.3% of Treatt shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Synthomer pays an annual dividend of GBX 25 per share and has a dividend yield of 10.9%. Treatt pays an annual dividend of GBX 8 per share and has a dividend yield of 2.1%. Synthomer pays out -1,000.0% of its earnings in the form of a dividend. Treatt pays out 4,444.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Synthomer is clearly the better dividend stock, given its higher yield and lower payout ratio.
Synthomer has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Treatt has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.
Treatt has a net margin of 7.42% compared to Treatt's net margin of -5.83%. Synthomer's return on equity of 8.07% beat Treatt's return on equity.
Summary
Treatt beats Synthomer on 12 of the 20 factors compared between the two stocks.
Get Treatt News Delivered to You Automatically
Sign up to receive the latest news and ratings for TET and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools